Bryan Cullen

Overview:

My laboratory has for sometime been interested in understanding the molecular biology of the replication cycle of the pathogenic retrovirus HIV-1. Because HIV-1 gene expression is primarily regulated by specific RNA:protein interactions, my laboratory has also become interested in the more general area of RNA sequence mediated gene regulation, including nuclear mRNA export and the phenomenon of RNA interference.

In the past, my laboratory has worked extensively on Tat, the transcriptional regulator encoded by HIV-1, and on Rev, a virally encoded nuclear mRNA export factor. Our major focus at present is a third HIV-1 regulatory protein termed Vif. In the absence of Vif, HIV-1 virions are produced normally but are largely non-infectious. It has now been demonstrated that Vif functions to block an innate human antiretroviral defense pathway that relies on a factor called APOBEC3G or CEM15. In the absence of Vif, APOBEC3G is packaged into virions and induces degradation of the HIV-1 genome during reverse transcription in target cells. Vif directly interacts with APOBEC3G and thereby allows reverse transcription to proceed unimpeded. Among other issues, we are currently interested in how APOBEC3G is packaged into virions and in how Vif blocks APOBEC3G function. The role of APOBEC3G in cellular defense against other retroviruses and retrotransposons is also an area of interest.

A second major research area in my group relates to how microRNA precursors are processed to yield mature microRNAs and how microRNAs, and the closely related small interfering RNAs, function in human cells. We were the first group to demonstrate overexpression of human microRNAs and therefore have a system in place which should allow us to make rapid progress in this area. We also remain interested in using RNA interference to determine the role of specific cellular factors in different processes, including HIV-1 replication and nuclear mRNA export.

Positions:

James B. Duke Distinguished Professor of Molecular Genetics and Microbiology

Molecular Genetics and Microbiology
School of Medicine

Director, Center for Virology

Molecular Genetics and Microbiology
School of Medicine

Professor of Molecular Genetics and Microbiology

Molecular Genetics and Microbiology
School of Medicine

Professor in Medicine

Medicine, Rheumatology and Immunology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

Ph.D. 1984

University of Medicine and Dentistry of New Jersey

Grants:

Aids Research

Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Duke University Center For Aids Research

Awarded By
National Institutes of Health
Role
Co-Principal Investigator
Start Date
End Date

TM-SU Interaction in the Native HIV/SIV Env

Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Illumina Hi-Seq 2000 Sequencing System

Administered By
Institutes and Centers
Awarded By
National Institutes of Health
Role
Major User
Start Date
End Date

Epitranscriptomic modification of HIV-1 transcripts: Effects of drugs of abuse

Administered By
Molecular Genetics and Microbiology
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Publications:

Probing RNA Conformational Equilibria within the Functional Cellular Context.

Low-abundance short-lived non-native conformations referred to as excited states (ESs) are increasingly observed in vitro and implicated in the folding and biological activities of regulatory RNAs. We developed an approach for assessing the relative abundance of RNA ESs within the functional cellular context. Nuclear magnetic resonance (NMR) spectroscopy was used to estimate the degree to which substitution mutations bias conformational equilibria toward the inactive ES in vitro. The cellular activity of the ES-stabilizing mutants was used as an indirect measure of the conformational equilibria within the functional cellular context. Compensatory mutations that restore the ground-state conformation were used to control for changes in sequence. Using this approach, we show that the ESs of two regulatory RNAs from HIV-1, the transactivation response element (TAR) and the Rev response element (RRE), likely form in cells with abundances comparable to those measured in vitro, and their targeted stabilization may provide an avenue for developing anti-HIV therapeutics.
Authors
Ganser, LR; Chu, C-C; Bogerd, HP; Kelly, ML; Cullen, BR; Al-Hashimi, HM
MLA Citation
Ganser, Laura R., et al. “Probing RNA Conformational Equilibria within the Functional Cellular Context.Cell Rep, vol. 30, no. 8, Feb. 2020, pp. 2472-2480.e4. Pubmed, doi:10.1016/j.celrep.2020.02.004.
URI
https://scholars.duke.edu/individual/pub1433123
PMID
32101729
Source
pubmed
Published In
Cell Reports
Volume
30
Published Date
Start Page
2472
End Page
2480.e4
DOI
10.1016/j.celrep.2020.02.004

Epigenetic silencing by the SMC5/6 complex mediates HIV-1 latency.

After viral entry and reverse transcription, HIV-1 proviruses that fail to integrate are epigenetically silenced, but the underlying mechanism has remained unclear. Using a genome-wide CRISPR/Cas9 knockout screen, we identified the host SMC5/6 complex as essential for this epigenetic silencing. We show that SMC5/6 binds to and then SUMOylates unintegrated chromatinized HIV-1 DNA. Inhibition of SUMOylation, either by point mutagenesis of the SMC5/6 component NSMCE2-a SUMO E3 ligase-or using the SUMOylation inhibitor TAK-981, prevents epigenetic silencing, enables transcription from unintegrated HIV-1 DNA and rescues the replication of integrase-deficient HIV-1. Finally, we show that blocking SMC5/6 complex expression, or inhibiting its SUMOylation activity, suppresses the establishment of latent HIV-1 infections in both CD4+ T cell lines and primary human T cells. Collectively, our data show that the SMC5/6 complex plays a direct role in mediating the establishment of HIV-1 latency by epigenetically silencing integration-competent HIV-1 proviruses before integration.
Authors
Irwan, ID; Bogerd, HP; Cullen, BR
MLA Citation
Irwan, Ishak D., et al. “Epigenetic silencing by the SMC5/6 complex mediates HIV-1 latency.Nat Microbiol, vol. 7, no. 12, Dec. 2022, pp. 2101–13. Pubmed, doi:10.1038/s41564-022-01264-z.
URI
https://scholars.duke.edu/individual/pub1557040
PMID
36376394
Source
pubmed
Published In
Nature Microbiology
Volume
7
Published Date
Start Page
2101
End Page
2113
DOI
10.1038/s41564-022-01264-z

Human Alphaherpesvirus MicroRNAs: Expression and Functions

Authors
Umbach, JL; Cullen, BR
MLA Citation
Umbach, Jennifer L., and Bryan R. Cullen. “Human Alphaherpesvirus MicroRNAs: Expression and Functions.” ALPHAHERPESVIRUSES: MOLECULAR VIROLOGY, 2011, pp. 391–99.
URI
https://scholars.duke.edu/individual/pub1550317
Source
wos-lite
Published Date
Start Page
391
End Page
399

Efficacy of Genome Editing in Infant Mice with Glycogen Storage Disease Type Ia

Authors
Arnson, B; Li, S; Gheorgiu, D; Brooks, E; Han, S-O; Ilich, E; Cullen, BR; Koeberl, DD
MLA Citation
Arnson, Benjamin, et al. “Efficacy of Genome Editing in Infant Mice with Glycogen Storage Disease Type Ia.” Molecular Therapy, vol. 30, no. 4, 2022, pp. 115–16.
URI
https://scholars.duke.edu/individual/pub1523945
Source
wos-lite
Published In
Molecular Therapy
Volume
30
Published Date
Start Page
115
End Page
116

Single Vector AAV Approach to Genome Editing in Pompe Disease

Authors
Arnson, B; Wang, J; Courtney, D; Han, S-O; Li, S; Cullen, BR; Bursac, N; Koeberl, D
MLA Citation
Arnson, Benjamin, et al. “Single Vector AAV Approach to Genome Editing in Pompe Disease.” Molecular Therapy, vol. 29, no. 4, 2021, pp. 291–291.
URI
https://scholars.duke.edu/individual/pub1483116
Source
wos-lite
Published In
Molecular Therapy
Volume
29
Published Date
Start Page
291
End Page
291